Clinical trials use electronic pulses to attack cancer cells

A groundbreaking way of getting stubborn cancer cells to respond to treatment has taken a major step with the commencement of clinical trials.

The product was developed by Irish medical devices company MitaMed, which is a spin out firm supported by UCC.

The method involves targeting cancer cells with electronic pulses because it was discovered that when this happens the tumours are more responsive to medication.